Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF) (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo joined Proactive to speak about how its three of its patent applications for candidates had been published by the Patent Cooperation Treaty (PCT).
The two executives explain how the three patent applications cover a range of the firm's so-called Family 1 and Family 2 compounds designed to deliver superior therapeutic benefits to psilocybin with lower overall metabolic and safety liabilities. Lanthier explains the patent publication reaffirms its approach and its first-to-file advantage.